Intellipharmaceutics (IPCI) Forum
Sign up Calendar Latest Topics
 
 
 


Reply
  Author   Comment  
Samsa1

Moderator
Registered:
Posts: 692
Reply with quote  #1 

TORONTO, ON / ACCESSWIRE / December 5, 2018 / Intellipharmaceutics International Inc. (NASDAQ and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received written notification (the ''Notification'')from The Nasdaq Stock Market LLC ('NASDAQ'') notifying the Company that a hearing with a Nasdaq Hearings Panel (the ''Panel'')has been scheduled for January 10, 2019.

As previously reported, the minimum bid price per share for the Company's common shares was below $1.00 for a period of 30 consecutive business days and, as a result, the Company is currently not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Due to the fact that the Company was already subject to monitoring by a Panel, it was not afforded the automatic 180-day grace period within which to regain compliance. The Notification indicated that all suspension and delisting action relating to the Company's common shares has been stayed, pending a final written decision by the Panel following the hearing. The Company intends to attend the hearing and present a plan of compliance at the hearing. The Company must demonstrate its ability to regain compliance with the deficiencies cited by Staff, as well as its ability to sustain long-term compliance with all applicable maintenance criteria.

The Company expects that its shares will continue to be listed and traded on Nasdaq pending the hearing and the expiration of any extension granted by the Panel following the hearing.Pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an extension through May 28, 2019. However, there can be no assurance that the Company's presentation to the Panel will be successful, that the Panel will grant any extension or that the Company will be able to regain compliance with all applicable requirements for continued listing on Nasdaq.

The Company's common shares are also listed on the Toronto Stock Exchange (the ''TSX'') and the Company's non-compliance with the Nasdaq listing requirements does not affect the Company's compliance status with the TSX.

0
Samsa1

Moderator
Registered:
Posts: 692
Reply with quote  #2 
Well, one thing that I noticed was different in this PR than the previous was the following statement.
Quote:
The Company expects that its shares will continue to be listed and traded on Nasdaq pending the hearing and the expiration of any extension granted by the Panel following the hearing


Previous ones were not as optimistic.  Now, that aside one has to ask themselves, why would they need or go to the hearing to present a plan ? 
Quote:
The Company intends to attend the hearing and present a plan of compliance at the hearing


To me, this implies that they do not expect to reach $1 and be in compliance going into the meeting.  This also implies that they need the extension to the May 28, deadline which is referenced in the PR.  

So, they do not expect the price to be above $1 up through May?    Which means what?  They are not intending on refiling Rexista until then?  Or they don't expect any price pop on news of refiling?

The sad part of this, is the date.  "the Panel has the discretion to grant the Company an extension through May 28, 2019."   Most likely His wonderful plan will be sneaking in another Reverse Split at the next share holder's meeting!   I know those proxies are worded in a way that when you give your vote, you are also giving them power to vote on "other issues that may arise"   My guess is he just plans on doing another Reverse Split at the next annual meeting and getting us above $1 that way. 

Normally, I would have said we probably would see a Rexista deal or Regabatin deal or something else, but after the way he handled things this past year.  I think we need to seriously consider he has no plan other than to stall things until the annual meeting and do another RS.   Lets face it, he put out 5 PR's which were positive in nature and we got no price appreciation.  so, It would not surprise me he feels he has no choice or no other control other than another RS.  
0
Previous Topic | Next Topic
Print
Reply

Quick Navigation:

Easily create a Forum Website with Website Toolbox.